Key result
Early rhythm control linked to ~19% fewer cardiovascular complications versus rate control in low-risk AF.
Why the study?
To investigate whether the benefits of early rhythm control seen in EAST-AFNET 4 can be generalized to recently diagnosed AF patients with low stroke risk.
Does early rhythm control therapy reduce the composite outcome of cardiovascular death, ischemic stroke, heart failure hospitalization, or myocardial infarction compared to rate control in patients with recently diagnosed atrial fibrillation, including low-risk patients?
Cohort (n=54,216)
Yes
Does early rhythm control therapy reduce the composite outcome of cardiovascular death, ischemic stroke, heart failure hospitalization, or myocardial infarction compared to rate control in patients with recently diagnosed atrial fibrillation, including low-risk patients?
Early rhythm control therapy is associated with a reduced risk of adverse cardiovascular outcomes compared to rate control even in low-risk patients with recently diagnosed atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May support early rhythm control in low-risk AF; hypothesis-generating pending RCT confirmation.
Background: Rhythm control is associated with lower risk for adverse cardiovascular outcomes compared with usual care among patients recently diagnosed with atrial fibrillation (AF) with a CHA2DS2-VASc score of approximately 2 or greater in EAST-AFNET 4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial). Objective: To investigate whether the results can be generalized to patients with low stroke risk. Design: Population-based cohort study. Setting: Nationwide claims database of the Korean National Health Insurance Service. Participants: 54 216 patients with AF having early rhythm control (antiarrhythmic drugs or ablation) or rate control therapy that was initiated within 1 year of the AF diagnosis. Measurements: The effect of early rhythm control on the primary composite outcome of cardiovascular death, ischemic stroke, hospitalization for heart failure, or myocardial infarction was compared between eligible and ineligible patients for EAST-AFNET 4 (CHA2DS2-VASc score, approximately 0 to 1) using propensity overlap weighting. Results: In total, 37 557 study participants (69.3%) were eligible for the trial (median age, 70 years; median CHA2DS2-VASc score, 4), among whom early rhythm control was associated with lower risk for the primary composite outcome than rate control (hazard ratio, 0.86 [95% CI, 0.81 to 0.92]). Among the 16 659 low-risk patients (30.7%) who did not meet the inclusion criteria (median age, 54 years; median CHA2DS2-VASc score, 1), early rhythm control was consistently associated with lower risk for the primary outcome (hazard ratio, 0.81 [CI, 0.66 to 0.98]). No significant differences in safety outcomes were found between the rhythm and rate control strategies regardless of trial eligibility. Limitation: Residual confounding. Conclusion: In routine clinical practice, the beneficial association between early rhythm control and cardiovascular complications was consistent among low-risk patients regardless of trial eligibility. Primary Funding Source: The Ministry of Health and Welfare and the Ministry of Food and Drug Safety, Republic of Korea.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2022) conducted a cohort in Atrial fibrillation (n=54,216). Early rhythm control (antiarrhythmic drugs or ablation) vs. Rate control therapy was evaluated on Composite of cardiovascular death, ischemic stroke, hospitalization for heart failure, or myocardial infarction (HR 0.81, 95% CI 0.66 to 0.98). Early rhythm control was associated with a lower risk of cardiovascular complications compared to rate control in low-risk atrial fibrillation patients.
Synapse has enriched 10 related papers. Consider them for comparative context: